An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

In an exclusive poll for City AM, Joanna Hodgson surveys major firms to see if hybrid working is still king in the UK ...

In 1990, the US Food and Drug Administration (FDA ... while Zeneca Shareholders held 53.5%. AstraZeneca’s corporate headquarters were chosen to be in London, United Kingdom, while its R&D ...

According to Syed Mohammed Idid, general manager of strategic communications and stakeholder engagement at West Coat ...

NASA will host a news conference at 12 p.m. EST Friday, Jan. 31, to discuss a new telescope that will improve our understanding of how the universe evolved and search for key ingredients for life in ...

AstraZeneca has confirmed that some of its current ... years to become the second-largest pharma market globally after the US, driven by a massive ageing population with rising spending power ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

“As the company continues to pursue a footprint of more than 2,000 jobs in Mississauga and Peel Region, Ontario’s world-class ...

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies MISSISSAUGA, ON, Jan. 23, 2025 /CNW ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

AstraZeneca (NASDAQ:AZN ... This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...